Difference between revisions of "Clopidogrel (Plavix)"
Jump to navigation
Jump to search
(updated content) |
m |
||
| Line 16: | Line 16: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Hematology medications]] | [[Category:Hematology medications]] | ||
| − | [[Category: | + | [[Category:Antiplatelet agents]] |
[[Category:P2Y12 ADP inhibitors]] | [[Category:P2Y12 ADP inhibitors]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1997]] | ||
Revision as of 15:14, 3 November 2014
General information
Class/mechanism: Irreversible thienopyridine class inhibitor of the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets, inhibiting platelet activation and aggregation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Clopidogrel (Plavix) manufacturer's patient information[4]
- Clopidogrel (Plavix) package insert PDF pages 7-8[1]
- Clopidogrel (Plavix) patient drug information (UpToDate)[5]